OTC:ZOMDF Zomedica (ZOMDF) Stock Price, News & Analysis $0.04 0.00 (-0.74%) As of 06/27/2025 03:57 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartSEC FilingsShort InterestBuy This Stock About Zomedica Stock (OTC:ZOMDF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Zomedica alerts:Sign Up Key Stats Today's Range$0.04▼$0.0550-Day Range$0.04▼$0.0652-Week Range$0.02▼$0.17Volume2.61 million shsAverage Volume4.86 million shsMarket Capitalization$39.69 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewZomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.Read More… Zomedica Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks6th Percentile Overall ScoreZOMDF MarketRank™: Zomedica scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Zomedica. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Zomedica is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zomedica is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.06% of the float of Zomedica has been sold short.Short Interest Ratio / Days to CoverZomedica has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Zomedica has recently decreased by 18.21%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldZomedica does not currently pay a dividend.Dividend GrowthZomedica does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.06% of the float of Zomedica has been sold short.Short Interest Ratio / Days to CoverZomedica has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Zomedica has recently decreased by 18.21%, indicating that investor sentiment is improving significantly. News and Social Media0.6 / 5News SentimentN/A Search Interest3 people have searched for ZOMDF on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Zomedica to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Zomedica insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.58% of the stock of Zomedica is held by insiders.Percentage Held by InstitutionsOnly 8.95% of the stock of Zomedica is held by institutions.Read more about Zomedica's insider trading history. Receive ZOMDF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zomedica and its competitors with MarketBeat's FREE daily newsletter. Email Address ZOMDF Stock News HeadlinesZomedica Corp.: Zomedica's Fourth Friday at Four Webinar Returns: Spotlight on TRUFORMA Diagnostic Platform - Revolutionizing In-Clinic DiagnosticsJune 19, 2025 | finanznachrichten.deZomedica Corp (ZOMDF) Q1 2025 Earnings Call Highlights: Record Revenue Amid Strategic ChallengesMay 16, 2025 | finance.yahoo.comGold Just Jumped Again. Here’s How to Get PaidGold prices just spiked again. As I write this, gold is trading near $3,400 an ounce. But here's the thing… You don't need to bet on gold prices going higher. June 28 at 2:00 AM | Investors Alley (Ad)Zomedica CFO Scott Jordan Resigns, Interim Replacement NamedApril 30, 2025 | tipranks.comZomedica Corp. (ZOMDF)April 12, 2025 | finance.yahoo.comZomedica Corp. (ZOMDF): Among Stocks Insiders Were Buying In Q1 2025April 2, 2025 | finance.yahoo.comZomedica Corp. (ZOMDF): Among Stocks Insiders Were Buying In Q1 2025April 1, 2025 | insidermonkey.comSee More Headlines ZOMDF Stock Analysis - Frequently Asked Questions How have ZOMDF shares performed this year? Zomedica's stock was trading at $0.1229 on January 1st, 2025. Since then, ZOMDF shares have decreased by 67.0% and is now trading at $0.0405. View the best growth stocks for 2025 here. How do I buy shares of Zomedica? Shares of ZOMDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTC SectorManufacturing Industry Pharmaceutical Preparations Sub-IndustryPharmaceutical Products Current SymbolOTC:ZOMDF Previous SymbolOTC:ZOMDF CIK1684144 Webwww.zomedica.com Phone734 369 2555FaxN/AEmployees50Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares979,950,000Free FloatN/AMarket Cap$39.69 million OptionableN/A Beta1.56 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (OTC:ZOMDF) was last updated on 6/28/2025 by MarketBeat.com Staff From Our PartnersCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump set to Boost Social Security Checks by 400%?If you're currently collecting—or planning to collect—Social Security benefits, there's an urgent development ...InvestorPlace | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zomedica Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zomedica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.